Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) has announced receiving approval from the National Medical Products Administration (NMPA) to conduct Phase II clinical trials for its Category 1 drug UBT251 in chronic kidney disease (CKD). This marks a significant step forward in the development of innovative therapies for CKD.
UBT251: Mechanism and Development
UBT251 is a triple agonist targeting glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1 (GLP-1), and glucagon (GCG) receptors. It is the first of its kind synthesized in China and is currently being investigated in clinical studies for adult type 2 diabetes, overweight or obesity, and nonalcoholic fatty liver disease. The drug has demonstrated efficacy and safety in these indications, positioning it as a potential new treatment option for patients with CKD.
Future Outlook
With the NMPA’s approval to proceed with Phase II trials, United Laboratories is poised to further explore the therapeutic potential of UBT251 in chronic kidney disease. This development underscores the company’s commitment to advancing innovative treatments for metabolic and renal conditions.-Fineline Info & Tech
Leave a Reply